Source: https://patents.google.com/patent/US8470865B2/en
Timestamp: 2019-07-21 05:10:29
Document Index: 63014283

Matched Legal Cases: ['§119', 'Application No. 60', '§119', 'Application No. 95', 'Application No. 95', 'Application No. 95', 'Application No. 95', 'Application No. 95', 'Application No. 95', 'Application No. 95']

US8470865B2 - Methods and compositions for increasing the anaerobic working capacity in tissues - Google Patents
US8470865B2
US8470865B2 US13/356,182 US201213356182A US8470865B2 US 8470865 B2 US8470865 B2 US 8470865B2 US 201213356182 A US201213356182 A US 201213356182A US 8470865 B2 US8470865 B2 US 8470865B2
US13/356,182
US20120190717A1 (en
2011-12-21 First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33303070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US8470865(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
2012-01-23 Application filed by Natural Alternatives International Inc filed Critical Natural Alternatives International Inc
2012-03-02 Assigned to NATURAL ALTERNATIVES INTERNATIONAL reassignment NATURAL ALTERNATIVES INTERNATIONAL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HARRIS, ROGER, DUNNETT, MARK
2012-05-03 US case 4:12-cv-01388 filed litigation https://portal.unifiedpatents.com/litigation/Texas%20Southern%20District%20Court/case/4%3A12-cv-01388 Source: District Court Jurisdiction: Texas Southern District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
2012-07-26 Publication of US20120190717A1 publication Critical patent/US20120190717A1/en
2013-06-14 US case 4:13-cv-01742 filed litigation https://portal.unifiedpatents.com/litigation/Texas%20Southern%20District%20Court/case/4%3A13-cv-01742 Source: District Court Jurisdiction: Texas Southern District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
2013-06-24 US case 4:13-cv-01834 filed litigation https://portal.unifiedpatents.com/litigation/Texas%20Southern%20District%20Court/case/4%3A13-cv-01834 Source: District Court Jurisdiction: Texas Southern District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
2013-06-25 Publication of US8470865B2 publication Critical patent/US8470865B2/en
This application is a continuation of U.S. patent application Ser. No. 12/806,356 filed Aug. 10, 2010, now U.S. Pat. No. 8,129,422, which is a continuation of U.S. patent application Ser. No. 12/231,240, filed Aug. 29, 2008, now U.S. Pat. No. 7,825,084, which is a continuation of U.S. patent application Ser. No. 10/717,217, filed Nov. 18, 2003, now U.S. Pat. No. 7,504,376, which claims the benefit of priority under 35 U.S.C. §119(e) of U.S. Provisional Application No. 60/462,238 filed Apr. 10, 2003 and that is a continuation-in-part (CIP) of U.S. application Ser. No. 10/209,169, filed Jul. 30, 2002, now U.S. Pat. No. 6,680,294, which is a continuation of U.S. application Ser. No. 09/757,782, filed Jan. 9, 2001, now U.S. Pat. No. 6,426,361, which is a continuation of U.S. application Ser. No. 09/318,530, filed May 25, 1999, now U.S. Pat. No. 6,172,098, which is a divisional of U.S. application Ser. No. 08/909,513, filed Aug. 12, 1997, now U.S. Pat. No. 5,965,596, which claims the benefit of foreign priority under 35 U.S.C. §119 to United Kingdom Application Nos. 9621914.2, filed Oct. 21, 1996, and 9616910.7, filed Aug. 12, 1996. The aforementioned applications are incorporated by reference in their entirety.
The compositions can be a dietary supplement that can be ingested, injected, or absorbed through the skin. Preferably, the compositions can be administered in one or more doses per day. The beta-alanine dosage can be between about 1 milligram and about 200 milligrams per kilogram body weight or the dose of a peptide of beta-alanine (e.g. carnosine) from 2.5 milligrams to 500milligrams per kilogram body weight. In one aspect, the total amount of beta-alanine (or other composition of the invention) administered can be at least 200 mg, from 200 mg to 5 g, or from 5 g or more per day for a human. A single dose of active ingredient, e.g., beta-alanine, carnosine, anserine, or balenine, or mixtures thereof, may be formulated to be in the amount about 200, 400, 800 mg or more. The creatine (e.g., creatine monohydrate) dosage, or dosage of other compositions of the invention, can be between about 5 milligrams to 200 milligrams per kilogram body weight. The L-histidine dosage, or dosage of other compositions of the invention, can be between about 1 milligram to 100 milligrams per kilogram body weight. The simple carbohydrate (e.g., glucose) dosage, or dosage of compositions of the invention, can be between about 0.5 and 2.0 grams per kilogram body weight.
In one aspect, the total amount of a peptide of beta-alanine, for example, carnosine, anserine or balenine that can be administered per day may be at least 500 mg, between about 500 mg to about 5 g, between about 5 g to about 16 g, or greater than 16g. A single dose of a peptide of beta-alanine creatine, anserine or balenine, or mixtures thereof, may be formulated to be in the amount of 0.5, 1, 1.5, or 2 g (for each, or all, or the peptides in a formulation comprising a mixture).
time @ time @ time @ Total
MVC MVC 66% MVC 66% MVC 66% MVC Contraction
Summary of subjects' physical characteristics for each
of the three treatment groups:
Five subjects were allocated to one of three treatment groups (1, 2, and 3). During the study, their diet was supplemented with either beta-alanine or carnosine as described in Table 9 (FIG. 17). The supplements were provided in soft gelatine capsules containing either 400mg beta alanine or 500mg carnosine.
The muscle beta-alanine concentration was below the limit of detection (<0.2 mmol/kg dm) before and at the end of supplementation. In some subjects, a final dose of beta-alanine was taken within 1 to 2 hours of the final muscle biopsy. There was no change in the muscle histidine concentration with supplementation with either beta-alanine or carnosine, the latter having the potential to release histidine into the general circulation. There was no decrease in the histidine concentration in response to the increased synthesis of carnosine (each mole requiring one mole of histidine).
The changes in the muscle buffering capacity help maintain the intracellular microenvironment during intense exercise, countering the accumulation of H. As such, supplementation with beta-alanine or compounds delivering beta-alanine on ingestion may have a positive effect on exercise capacity in sports and those general daily activities leading to lactate accumulation. In view of the other chemical activities ascribed to carnosine (as an anti-oxidant and anti-glycating agent), an increase in carnosine concentration may have other beneficial effects apart from those arising from an increase in muscle buffering capacity.
2. The method of claim 1, further comprising providing an amount of L-histidine to the blood or blood plasma effective to increase beta-alanylhistidine dipeptide synthesis in the tissue.
3. The method of claim 1, further comprising increasing a concentration of creatine in the tissue.
4. The method of claim 3, further comprising providing an amount of L-histidine to the blood or blood plasma effective to increase beta-alanylhistidine dipeptide synthesis in the tissue.
5. The method of claim 3, wherein increasing the amount of creatine in the tissue includes providing an amount of creatine to the blood or blood plasma effective to increase the concentration of creatine in the tissue.
6. The method of claim 5, further comprising providing an amount of L-histidine to the blood or blood plasma effective to increase beta-alanylhistidine dipeptide synthesis in the tissue.
7. The method of claim 1, wherein the providing step is by ingestion.
8. The method of claim 1, wherein the providing step is by infusion.
9. The method of claim 1, wherein the tissue is a skeletal muscle.
US13/356,182 1996-08-12 2012-01-23 Methods and compositions for increasing the anaerobic working capacity in tissues Expired - Lifetime US8470865B2 (en)
US20120190717A1 US20120190717A1 (en) 2012-07-26
US8470865B2 true US8470865B2 (en) 2013-06-25
US20130261336A1 (en) * 1996-08-12 2013-10-03 Natural Alternatives International, Inc. Methods and compositions for increasing the anaerobic working capacity in tissues
Admin, Beta-Alanine Review, (May 23, 2008) Retrieved from: -www.musclesweb.net/blog/beta-alanine-review/ [Retrieved on Jan. 5, 2010] [2 pages].
Babizhayev et al., "L-carnosine (beta-alanyl-L-histidine) and carcinine (beta-alanylhistamine) act as natural antioxidants with hydroxyl-radical-scavenging and lipid-peroxidase activities," Biochem J. 304 (Pt 2):509-5l6 (1994).
Dunnett, M. and R. Harris, "High-performance liquid chromatographic determination of imidazole dipeptides, histidine, l-methylhistidine and 3-methylhistidine in muscle and individual muscle fibers," J. Chromatogr. B. Biomed. Appl., 688:47-55 (1997).
Dunnett, M., "Carnosine metabolism and function in the thoroughbread horse (anaerobic exercise)," Dissertation(Open University) vol. 57/04-C of dissertation abstracts 1143 (1996).
Dunnett, M., "Carnosine Metabolism and Function in the Thoroughbred Horse", Full Dissertation, See (Open University) vol. 57/04-C of dissertation abstracts 1143 (1996).
Harris et al., "The plasma concentration-time profile of beta-alanine using a controlled release formulation (Carnosyn®)," Meeting Abstract, The FASEB Journal 22:701.9 (2008).
In the U.S. Patent and Trademark Office, Inter Partes Reexamination for Patent No. 8129422, Determination-Reexam Ordered in re: Reexam Application No. 95/002,048, dated Aug. 17, 2012, 22 pages.
In the U.S. Patent and Trademark Office, Inter Partes Reexamination for Patent No. 8129422, Determination—Reexam Ordered in re: Reexam Application No. 95/002,048, dated Aug. 17, 2012, 22 pages.
In the U.S. Patent and Trademark Office, Inter Partes Reexamination for Patent No. 8129422, Reexam Office Action in re: Reexam Application No. 95/002,048, dated Aug. 17, 2012, 24 pages.
In the U.S. Patent and Trademark Office, Inter Partes Reexamination for Patent No. 8129422, Reexam Office Action in re: Reexam Application No. 95/002,048, dated Oct. 16, 2012, 28 pages.
In the U.S. Patent and Trademark Office, Inter Partes Reexamination, for Patent No. 8067381, Determination-Reexam Ordered in re: Reexam Application No. 95/002,001, dated Jul. 26, 2012, 19 pages.
In the U.S. Patent and Trademark Office, Inter Partes Reexamination, for Patent No. 8067381, Determination—Reexam Ordered in re: Reexam Application No. 95/002,001, dated Jul. 26, 2012, 19 pages.
In the U.S. Patent and Trademark Office, Inter Partes Reexamination, for Patent No. 8067381, Reexam Office Action in re: Reexam Application No. 95/002,001, dated Jul. 26, 2012, 19 pages.
Johnson, P., "Does Beta-Alanine work?" (Jul. 9, 2007) Retrieved from: vvww.betaalanine.info/background-on-beta-alanine/ [Retrieved on Jan. 5, 2010] [2 pages].
Kendrick et al., "The effect of beta-alanine (Carnosyn(TM)) supplementation on muscle carnosine synthesis during 4 weeks using a one-leg training model," 3rd Annual International Society of Sports Nutrition Conference, Las Vegas, Jun. 2006.
Kvalnes-Krick et al., "Cloning, Sequencing, and Expression of cDNA Encoding beta-Alanine Synthase from Rat Liver," J. of Bio. Chem., 268(8), pp. 5686-5693 (1993).
Office Action, issued Oct. 19, 2009, in connection with U.S. Appl. No. 12/231,240.
Skulachev, V., [Carnosine and anserine as specialized pH-buffers-hydrogen ion carriers-article in Russian] Biokhimiya 57(9):1311-1316 (1992).
Tallon, "Research Summaries on beta-Alanine/Histidine Supplementation and its Role in Hydrogen-Binding, pH-Controlling, and Carnosine Storage in Skeletal Muscle," iSatori Technologies, Product No. 17805, 8 pages (2005).
US8993610B2 (en) * 1996-08-12 2015-03-31 Natural Alternatives International, Inc. Methods and compositions for increasing the anaerobic working capacity in tissues
Earnest et al. 1996 High-performance capillary electrophoresis-pure creatine monohydrate reduces blood lipids in men and women
DK2153870T3 (en) 2014-03-10 COMPOSITIONS COMPRISING ornithine and phenylacetate phenylbutyrate OR TREATMENT hepatic encephalopathy
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HARRIS, ROGER;DUNNETT, MARK;SIGNING DATES FROM 20040701 TO 20040707;REEL/FRAME:027795/0344